"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-10-567
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine, and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2011English

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2018English

Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Sorafenib in Combination With Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-Line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Clinical Cancer Research
Cancer ResearchOncology
2013English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Discontinuation of First-Line Bevacizumab in Metastatic Colorectal Cancer: The BEAWARE Italian Observational Study

Tumori
MedicineCancer ResearchOncology
2019English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy